Brief: Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis
March 16 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS: SUN PHARMA ANNOUNCES US FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE (SBLA) APPLICATION FOR ILUMYA® (TILDRAKIZUMAB-ASMN) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS SUN PHARMA - FDA REGULATORY ACTION DATE FOR ILUMYA SBLA EXPECTED BY OCTOBER 29, 2026 Source text: ID:nPn7NWHdSa Further company coverage: SUN.NS ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses